The Cardiovascular Effect of Single Injection and Toxicologic Effects of Repetitive 2-Week Intravenous Administration of Activin A/BMP-2 Chimera in Beagle Dog.
Jae Hyup LeeSenyon ChoeShihuan HanPublished in: Cardiovascular toxicology (2019)
This study was performed for the purpose to evaluate the effect of activin A/BMP-2 chimera (AB204) on cardiovascular system and toxicological effect in beagle dogs. When administered AB204 at the dose of 0.32 mg/kg via intravenous injection in beagle dogs, there were no changes in systolic, diastolic and mean blood pressure as well as in pulse rate, in addition that there were no differences in ORS complex, PR interval, R-R interval, QT interval and QTcV interval on the electrocardiography. Also, when administered AB204 at the doses of 0.25 and 0.5 mg/kg/day via repetitive intravenous injection for 2 weeks, it did not cause any significant changes in general symptoms, weight, food intake, ophthalmologic abnormality, urine, hematology, serum biochemistry, organ weight and autopsy values. Therefore, AB204 did not affect cardiovascular functions including blood pressure, pulse rate and ECG, when administered at the dose of ≤0.32 mg/kg via single intravenous injection in male beagle dogs. When it was administered at the dose of 0.5 mg/kg repetitive intravenous injection for 2 weeks, it did not show any toxicity.
Keyphrases
- blood pressure
- high dose
- heart rate
- ultrasound guided
- high frequency
- hypertensive patients
- left ventricular
- mesenchymal stem cells
- body mass index
- heart failure
- physical activity
- heart rate variability
- oxidative stress
- blood glucose
- randomized controlled trial
- type diabetes
- clinical trial
- low dose
- bone marrow
- body weight
- ejection fraction
- bone regeneration
- glycemic control